Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Rituximab SC in CD20+ DLBCL or Follicular NHL
NCT02406092Phase 3Completed
- Sponsor
- Roche
- Start
- Oct 2015
- Primary completion
- Jun 2021
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 3 trial of rituximab in diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), sponsored by Roche. Started Oct 2015; status: completed.
02
Drugs
rituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT02406092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02406092.